Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
DB15057InvestigationalSmall molecule
NUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).
- Mechanism
- Curator reviewed
Pharmacologically active on Ribonucleoside-diphosphate reductase large subunit
- Formula / weight
- C25H27F2N4O8P · 580.482 g/mol (avg)
- Code names
- BIO-1031 · NUC-1031 · NUC-1031, (S)-
Resolves to
Structure
InChIKey
NHTKGYOMICWFQZ-UHFFFAOYSA-NSMILESCC(NP(=O)(OCC1OC(N2C=CC(N)=NC2=O)C(F)(F)C1O)OC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1Targets
What you can answer from here — as of October 11, 2026
Which drugs share a target with Fosgemcitabine palabenamide, and which of those have an active Phase 3 trial?